Taurine is thus a promising metabolite for future studies on its involvement in FD retinal pathology and may be a good candidate metabolite for therapeutic interventions focused on mitigating the progressive optic atrophy observed in FD patients, as well as that of LHON and DOA. This evidence concerns the gene MT-ND4 and Fabry disease.